AZX 1103
Alternative Names: AZ-1103; AZX-1103Latest Information Update: 21 May 2024
Price :
$50 *
At a glance
- Originator AzurRx BioPharma
- Developer Entero Therapeutics
- Class Anti-infectives; Antibacterials; Antidiarrhoeals; Enzymes
- Mechanism of Action Enzyme replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nosocomial infections
Most Recent Events
- 16 May 2024 First Wave Biopharma is now called Entero Therapeutics
- 28 May 2022 No recent reports of development identified for preclinical development in Nosocomial-infections(Prevention) in France (PO)
- 13 Sep 2021 AzurRx BioPharma has acquired First Wave Bio and then later changed its name to First Wave BioPharma